FDA chides Eli Lilly for second misleading ad in 2 months, this time for diabetes blockbuster Trulicity
After neatly wrapping up concerns over a series of Emgality ads last month, Eli Lilly is back in hot water with the FDA's Office of Prescription Drug Promotion.
The ...